Ads
related to: sanofi pharmaceuticals
Search results
Public-private collaboration aims to take ALS therapies beyond ‘a shot in the dark’
FierceBiotech· 13 hours agoIn 2015, after spending nearly four decades grinding his way up the ladder at one of the world’s...
Insulin would cost $35 max under proposed Ohio bill
Ohio Capital Journal via Yahoo News· 7 days agoA bipartisan group of Ohio lawmakers has introduced a bill to cap the costs of the life-saving medication insulin to $35. Medication prices are rising,...
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in...
WRBL Columbus· 2 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer ...
Antinephrin Autoantibodies: Biomarker for Kidney Disease?
Medscape· 4 days agoUsing an innovative analysis technique, researchers identified antinephrin autoantibodies as markers...
The AI effect: How a hot computing tool is tying ‘bio’ and ‘tech’ closer than ever - San Francisco...
The Business Journals· 6 days agoJames Fraser had his doubts. After all, decades of scientific rigor say that discovering drugs —...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoDiabetic Kidney Disease Market Size to Worth USD 5.32 Bn By 2031 PR Newswire BURLINGAME, Calif., May 28, 2024 BURLINGAME, Calif., May 28, 2024 /PRNewswire/ -- According to Coherent Market Insights, the global diabetic kidney disease market size
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?
Zacks· 6 days agoFree Report) . Will the recent negative trend continue leading up to its next earnings release, or is BioMarin due for a breakout? Before we dive into how investors and analysts have reacted ...
Neurocrine Biosciences Announces CEO Succession Plan
FOX 4 Kansas City· 1 day agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's ...
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies | JD...
JD Supra· 6 days agoIts decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme ...
European Stocks Close Lower As Investors Await Crucial Economic Data
RTT News· 2 days agoEuropean stocks closed lower on Tuesday with investors largely making cautious moves, assessing the likely stance of the Federal Reserve and the Bank of England with regard to interest rates.
